Crescent Biopharma, Inc. (CBIO) analyst actions
Rating and price-target actions on CBIO in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the CBIO overview →
1 measured CBIO analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Comb | Press release | -1.38% | -6.99% |
Keep exploring
More CBIO: earnings → · SEC filings → · CBIO overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| EASTON PHARMS INC (EAPH) | 52 | 0.00% | 34% |
| VBI Vaccines, Inc. - Ordinary Shares (VBIV) | 52 | -0.01% | 40% |
| Careview Communications, Inc. (CRVW) | 51 | 0.00% | 12% |
| LIMITLESS VENTURE GRP INC (LVGI) | 51 | 0.00% | 33% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.